Last reviewed · How we verify

Salmeterol/Fluticasone propionate combination product — Competitive Intelligence Brief

Salmeterol/Fluticasone propionate combination product (Salmeterol/Fluticasone propionate combination product) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination. Area: Respiratory.

phase 3 Long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination Beta2-adrenergic receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Salmeterol/Fluticasone propionate combination product (Salmeterol/Fluticasone propionate combination product) — GlaxoSmithKline. Salmeterol/Fluticasone propionate combination product is a long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination that works by relaxing airway muscles and reducing inflammation in the lungs.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Salmeterol/Fluticasone propionate combination product TARGET Salmeterol/Fluticasone propionate combination product GlaxoSmithKline phase 3 Long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination Beta2-adrenergic receptor
Salmeterol 50 mcg via DISKUS Salmeterol 50 mcg via DISKUS GlaxoSmithKline marketed Long-acting beta2-adrenergic agonist (LABA) Beta2-adrenergic receptors
levalbuterol tartrate MDI levalbuterol tartrate MDI Sumitomo Pharma America, Inc. phase 3 Long-acting beta2-adrenergic receptor agonist beta2-adrenergic receptor
budesonide plus formoterol combination budesonide plus formoterol combination Chiesi Farmaceutici S.p.A. phase 3 Corticosteroid and long-acting beta2-adrenergic receptor agonist combination Beta2-adrenergic receptor
Symbicort Turbohaler Symbicort Turbohaler Pearl Therapeutics, Inc. phase 3 Corticosteroid and long-acting beta2-adrenergic receptor agonist combination Beta2-adrenergic receptor
Placebo to Salmeterol/fluticasone Placebo to Salmeterol/fluticasone Novartis phase 3 Long-acting beta2-adrenergic receptor agonist and corticosteroid Beta2-adrenergic receptor and glucocorticoid receptor
Symbicort TBH - Turbuhaler Symbicort TBH - Turbuhaler AstraZeneca phase 3 Corticosteroid and long-acting beta2-adrenergic receptor agonist combination Beta2-adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination class)

  1. GlaxoSmithKline · 1 drug in this class
  2. Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Salmeterol/Fluticasone propionate combination product — Competitive Intelligence Brief. https://druglandscape.com/ci/salmeterol-fluticasone-propionate-combination-product. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: